uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q3.691 | Q3 | What is the allele frequency of the SNP rs530391854 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs530391854 has an effect allele TA frequency of 0.0048 and non-effect allele T frequency of 0.9952. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs530391854'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_7280351', 'SNP': 'rs530391854', 'effect_allele': 'TA', 'effect_allele_frequency': 0.0048, 'non_effect_allele': 'T', 'non_effect_allele_frequency': 0.9952}] | general | Select, Calculate | Allele Frequency |
Q3.36 | Q3 | What is the allele frequency of the SNP rs189783021 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs189783021 has an effect allele T frequency of 0.0021 and non-effect allele C frequency of 0.9979. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs189783021'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_431031', 'SNP': 'rs189783021', 'effect_allele': 'T', 'effect_allele_frequency': 0.0021, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.9979}] | general | Select, Calculate | Allele Frequency |
Q3.910 | Q3 | What is the allele frequency of the SNP rs2965556 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs2965556 has an effect allele G frequency of 0.2121 and non-effect allele A frequency of 0.7879. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs2965556'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_9767166', 'SNP': 'rs2965556', 'effect_allele': 'G', 'effect_allele_frequency': 0.2120999999999999, 'non_effect_allele': 'A', 'non_effect_allele_frequency': 0.7879}] | general | Select, Calculate | Allele Frequency |
Q3.834 | Q3 | What is the allele frequency of the SNP rs114591714 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs114591714 has an effect allele C frequency of 0.001 and non-effect allele T frequency of 0.999. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs114591714'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_8901206', 'SNP': 'rs114591714', 'effect_allele': 'C', 'effect_allele_frequency': 0.001, 'non_effect_allele': 'T', 'non_effect_allele_frequency': 0.999}] | general | Select, Calculate | Allele Frequency |
Q3.1798 | Q3 | What is the allele frequency of the SNP rs9953556 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs9953556 has an effect allele T frequency of 0.0012 and non-effect allele C frequency of 0.9988. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs9953556'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_19204526', 'SNP': 'rs9953556', 'effect_allele': 'T', 'effect_allele_frequency': 0.0012, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.9988}] | general | Select, Calculate | Allele Frequency |
Q3.413 | Q3 | What is the allele frequency of the SNP rs11128072 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs11128072 has an effect allele T frequency of 0.4566 and non-effect allele C frequency of 0.5434. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs11128072'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_4224824', 'SNP': 'rs11128072', 'effect_allele': 'T', 'effect_allele_frequency': 0.4566, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.5434}] | general | Select, Calculate | Allele Frequency |
Q3.928 | Q3 | What is the allele frequency of the SNP rs139272524 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs139272524 has an effect allele A frequency of 0.3891 and non-effect allele G frequency of 0.6109. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs139272524'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_9908802', 'SNP': 'rs139272524', 'effect_allele': 'A', 'effect_allele_frequency': 0.3891, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.6109}] | general | Select, Calculate | Allele Frequency |
Q3.543 | Q3 | What is the allele frequency of the SNP rs55886014 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs55886014 has an effect allele G frequency of 0.2711 and non-effect allele A frequency of 0.7289. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs55886014'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_5657485', 'SNP': 'rs55886014', 'effect_allele': 'G', 'effect_allele_frequency': 0.2711, 'non_effect_allele': 'A', 'non_effect_allele_frequency': 0.7289}] | general | Select, Calculate | Allele Frequency |
Q3.765 | Q3 | What is the allele frequency of the SNP rs535463055 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs535463055 has an effect allele A frequency of 0.0031 and non-effect allele G frequency of 0.9969. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs535463055'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_8047724', 'SNP': 'rs535463055', 'effect_allele': 'A', 'effect_allele_frequency': 0.0031, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.9969}] | general | Select, Calculate | Allele Frequency |
Q3.1905 | Q3 | What is the allele frequency of the SNP rs2038893 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs2038893 has an effect allele A frequency of 0.4056 and non-effect allele G frequency of 0.5944. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs2038893'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_20402530', 'SNP': 'rs2038893', 'effect_allele': 'A', 'effect_allele_frequency': 0.4056, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.5944}] | general | Select, Calculate | Allele Frequency |
Q3.1071 | Q3 | What is the allele frequency of the SNP rs552450876 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs552450876 has an effect allele C frequency of 0.0007 and non-effect allele G frequency of 0.9993. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs552450876'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_11405032', 'SNP': 'rs552450876', 'effect_allele': 'C', 'effect_allele_frequency': 0.0007, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.9993}] | general | Select, Calculate | Allele Frequency |
Q3.1209 | Q3 | What is the allele frequency of the SNP rs3011598 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs3011598 has an effect allele A frequency of 0.2848 and non-effect allele G frequency of 0.7152. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs3011598'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_12895222', 'SNP': 'rs3011598', 'effect_allele': 'A', 'effect_allele_frequency': 0.2848, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.7152000000000001}] | general | Select, Calculate | Allele Frequency |
Q3.248 | Q3 | What is the allele frequency of the SNP rs552956174 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs552956174 has an effect allele T frequency of 0.0008 and non-effect allele C frequency of 0.9992. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs552956174'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_2470360', 'SNP': 'rs552956174', 'effect_allele': 'T', 'effect_allele_frequency': 0.0008, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.9992}] | general | Select, Calculate | Allele Frequency |
Q3.1431 | Q3 | What is the allele frequency of the SNP rs76972405 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs76972405 has an effect allele G frequency of 0.0093 and non-effect allele A frequency of 0.9907. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs76972405'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_15166045', 'SNP': 'rs76972405', 'effect_allele': 'G', 'effect_allele_frequency': 0.0092999999999999, 'non_effect_allele': 'A', 'non_effect_allele_frequency': 0.9907000000000001}] | general | Select, Calculate | Allele Frequency |
Q3.1137 | Q3 | What is the allele frequency of the SNP rs10813871 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs10813871 has an effect allele G frequency of 0.2542 and non-effect allele T frequency of 0.7458. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs10813871'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_12020833', 'SNP': 'rs10813871', 'effect_allele': 'G', 'effect_allele_frequency': 0.2542, 'non_effect_allele': 'T', 'non_effect_allele_frequency': 0.7458}] | general | Select, Calculate | Allele Frequency |
Q3.791 | Q3 | What is the allele frequency of the SNP rs900126042 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs900126042 has an effect allele G frequency of 0.0004 and non-effect allele T frequency of 0.9996. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs900126042'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_8366997', 'SNP': 'rs900126042', 'effect_allele': 'G', 'effect_allele_frequency': 0.0003999999999999, 'non_effect_allele': 'T', 'non_effect_allele_frequency': 0.9996000000000002}] | general | Select, Calculate | Allele Frequency |
Q3.1744 | Q3 | What is the allele frequency of the SNP rs17562828 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs17562828 has an effect allele A frequency of 0.1599 and non-effect allele G frequency of 0.8401. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs17562828'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_18554899', 'SNP': 'rs17562828', 'effect_allele': 'A', 'effect_allele_frequency': 0.1599, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.8401000000000001}] | general | Select, Calculate | Allele Frequency |
Q3.495 | Q3 | What is the allele frequency of the SNP rs569480203 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs569480203 has an effect allele G frequency of 0.0005 and non-effect allele A frequency of 0.9995. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs569480203'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_5203943', 'SNP': 'rs569480203', 'effect_allele': 'G', 'effect_allele_frequency': 0.0004999999999999, 'non_effect_allele': 'A', 'non_effect_allele_frequency': 0.9995}] | general | Select, Calculate | Allele Frequency |
Q3.157 | Q3 | What is the allele frequency of the SNP rs73087695 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs73087695 has an effect allele C frequency of 0.0024 and non-effect allele T frequency of 0.9976. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs73087695'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_1504644', 'SNP': 'rs73087695', 'effect_allele': 'C', 'effect_allele_frequency': 0.0023999999999999, 'non_effect_allele': 'T', 'non_effect_allele_frequency': 0.9976000000000002}] | general | Select, Calculate | Allele Frequency |
Q3.970 | Q3 | What is the allele frequency of the SNP rs566263729 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs566263729 has an effect allele C frequency of 0.0017 and non-effect allele T frequency of 0.9983. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs566263729'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_10420527', 'SNP': 'rs566263729', 'effect_allele': 'C', 'effect_allele_frequency': 0.0017, 'non_effect_allele': 'T', 'non_effect_allele_frequency': 0.9983}] | general | Select, Calculate | Allele Frequency |
Q3.860 | Q3 | What is the allele frequency of the SNP rs1738569 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs1738569 has an effect allele T frequency of 0.4529 and non-effect allele A frequency of 0.5471. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs1738569'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_9130358', 'SNP': 'rs1738569', 'effect_allele': 'T', 'effect_allele_frequency': 0.4528999999999999, 'non_effect_allele': 'A', 'non_effect_allele_frequency': 0.5471000000000001}] | general | Select, Calculate | Allele Frequency |
Q3.1325 | Q3 | What is the allele frequency of the SNP rs1047727922 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs1047727922 has an effect allele T frequency of 0.0008 and non-effect allele C frequency of 0.9992. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs1047727922'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_14047781', 'SNP': 'rs1047727922', 'effect_allele': 'T', 'effect_allele_frequency': 0.0008, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.9992}] | general | Select, Calculate | Allele Frequency |
Q3.632 | Q3 | What is the allele frequency of the SNP rs293103 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs293103 has an effect allele T frequency of 0.4921 and non-effect allele C frequency of 0.5079. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs293103'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_6596714', 'SNP': 'rs293103', 'effect_allele': 'T', 'effect_allele_frequency': 0.4921, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.5079}] | general | Select, Calculate | Allele Frequency |
Q3.692 | Q3 | What is the allele frequency of the SNP rs149971516 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs149971516 has an effect allele G frequency of 0.0073 and non-effect allele C frequency of 0.9927. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs149971516'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_7291899', 'SNP': 'rs149971516', 'effect_allele': 'G', 'effect_allele_frequency': 0.0072999999999999, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.9927000000000001}] | general | Select, Calculate | Allele Frequency |
Q3.1562 | Q3 | What is the allele frequency of the SNP rs555973334 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs555973334 has an effect allele C frequency of 0.0004 and non-effect allele T frequency of 0.9996. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs555973334'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_16696110', 'SNP': 'rs555973334', 'effect_allele': 'C', 'effect_allele_frequency': 0.0003999999999999, 'non_effect_allele': 'T', 'non_effect_allele_frequency': 0.9996000000000002}] | general | Select, Calculate | Allele Frequency |
Q3.575 | Q3 | What is the allele frequency of the SNP rs112115802 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs112115802 has an effect allele C frequency of 0.0049 and non-effect allele G frequency of 0.9951. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs112115802'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_5934430', 'SNP': 'rs112115802', 'effect_allele': 'C', 'effect_allele_frequency': 0.0049, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.9951}] | general | Select, Calculate | Allele Frequency |
Q3.1909 | Q3 | What is the allele frequency of the SNP rs75407362 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs75407362 has an effect allele T frequency of 0.0046 and non-effect allele C frequency of 0.9954. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs75407362'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_20420369', 'SNP': 'rs75407362', 'effect_allele': 'T', 'effect_allele_frequency': 0.0046, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.9954}] | general | Select, Calculate | Allele Frequency |
Q3.18 | Q3 | What is the allele frequency of the SNP rs575981866 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs575981866 has an effect allele T frequency of 0.0017 and non-effect allele C frequency of 0.9983. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs575981866'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_284708', 'SNP': 'rs575981866', 'effect_allele': 'T', 'effect_allele_frequency': 0.0017, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.9983}] | general | Select, Calculate | Allele Frequency |
Q3.130 | Q3 | What is the allele frequency of the SNP rs560817431 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs560817431 has an effect allele G frequency of 0.0025 and non-effect allele A frequency of 0.9975. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs560817431'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_1305302', 'SNP': 'rs560817431', 'effect_allele': 'G', 'effect_allele_frequency': 0.0024999999999999, 'non_effect_allele': 'A', 'non_effect_allele_frequency': 0.9975}] | general | Select, Calculate | Allele Frequency |
Q3.1361 | Q3 | What is the allele frequency of the SNP rs557147209 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs557147209 has an effect allele A frequency of 0.0016 and non-effect allele G frequency of 0.9984. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs557147209'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_14410264', 'SNP': 'rs557147209', 'effect_allele': 'A', 'effect_allele_frequency': 0.0016, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.9984}] | general | Select, Calculate | Allele Frequency |
Q3.1291 | Q3 | What is the allele frequency of the SNP rs545480865 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs545480865 has an effect allele T frequency of 0.0018 and non-effect allele C frequency of 0.9982. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs545480865'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_13654767', 'SNP': 'rs545480865', 'effect_allele': 'T', 'effect_allele_frequency': 0.0018, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.9982}] | general | Select, Calculate | Allele Frequency |
Q3.1969 | Q3 | What is the allele frequency of the SNP rs112937747 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs112937747 has an effect allele T frequency of 0.0013 and non-effect allele C frequency of 0.9987. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs112937747'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_20927175', 'SNP': 'rs112937747', 'effect_allele': 'T', 'effect_allele_frequency': 0.0013, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.9987}] | general | Select, Calculate | Allele Frequency |
Q3.935 | Q3 | What is the allele frequency of the SNP rs17866845 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs17866845 has an effect allele C frequency of 0.0009 and non-effect allele T frequency of 0.9991. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs17866845'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_10016042', 'SNP': 'rs17866845', 'effect_allele': 'C', 'effect_allele_frequency': 0.0009, 'non_effect_allele': 'T', 'non_effect_allele_frequency': 0.9991}] | general | Select, Calculate | Allele Frequency |
Q3.989 | Q3 | What is the allele frequency of the SNP rs75753617 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs75753617 has an effect allele C frequency of 0.165 and non-effect allele G frequency of 0.835. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs75753617'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_10598656', 'SNP': 'rs75753617', 'effect_allele': 'C', 'effect_allele_frequency': 0.165, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.835}] | general | Select, Calculate | Allele Frequency |
Q3.1965 | Q3 | What is the allele frequency of the SNP rs149504688 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs149504688 has an effect allele A frequency of 0.0004 and non-effect allele G frequency of 0.9996. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs149504688'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_20892662', 'SNP': 'rs149504688', 'effect_allele': 'A', 'effect_allele_frequency': 0.0004, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.9996}] | general | Select, Calculate | Allele Frequency |
Q3.193 | Q3 | What is the allele frequency of the SNP rs11898131 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs11898131 has an effect allele A frequency of 0.0014 and non-effect allele G frequency of 0.9986. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs11898131'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_1916586', 'SNP': 'rs11898131', 'effect_allele': 'A', 'effect_allele_frequency': 0.0014, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.9986}] | general | Select, Calculate | Allele Frequency |
Q3.1149 | Q3 | What is the allele frequency of the SNP rs10869981 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs10869981 has an effect allele T frequency of 0.0138 and non-effect allele C frequency of 0.9862. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs10869981'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_12139317', 'SNP': 'rs10869981', 'effect_allele': 'T', 'effect_allele_frequency': 0.0138, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.9862}] | general | Select, Calculate | Allele Frequency |
Q3.1001 | Q3 | What is the allele frequency of the SNP rs11988463 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs11988463 has an effect allele T frequency of 0.1462 and non-effect allele C frequency of 0.8538. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs11988463'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_10705536', 'SNP': 'rs11988463', 'effect_allele': 'T', 'effect_allele_frequency': 0.1462, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.8538}] | general | Select, Calculate | Allele Frequency |
Q3.1956 | Q3 | What is the allele frequency of the SNP rs550026014 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs550026014 has an effect allele C frequency of 0.0008 and non-effect allele T frequency of 0.9992. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs550026014'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_20830929', 'SNP': 'rs550026014', 'effect_allele': 'C', 'effect_allele_frequency': 0.0008, 'non_effect_allele': 'T', 'non_effect_allele_frequency': 0.9992}] | general | Select, Calculate | Allele Frequency |
Q3.1657 | Q3 | What is the allele frequency of the SNP rs138558179 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs138558179 has an effect allele G frequency of 0.0101 and non-effect allele C frequency of 0.9899. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs138558179'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_17703490', 'SNP': 'rs138558179', 'effect_allele': 'G', 'effect_allele_frequency': 0.0100999999999999, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.9899000000000001}] | general | Select, Calculate | Allele Frequency |
Q3.613 | Q3 | What is the allele frequency of the SNP rs6855375 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs6855375 has an effect allele T frequency of 0.0084 and non-effect allele A frequency of 0.9916. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs6855375'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_6337759', 'SNP': 'rs6855375', 'effect_allele': 'T', 'effect_allele_frequency': 0.0083999999999999, 'non_effect_allele': 'A', 'non_effect_allele_frequency': 0.9916000000000001}] | general | Select, Calculate | Allele Frequency |
Q3.183 | Q3 | What is the allele frequency of the SNP rs3771148 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs3771148 has an effect allele T frequency of 0.3897 and non-effect allele C frequency of 0.6103. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs3771148'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_1775541', 'SNP': 'rs3771148', 'effect_allele': 'T', 'effect_allele_frequency': 0.3897, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.6103000000000001}] | general | Select, Calculate | Allele Frequency |
Q3.305 | Q3 | What is the allele frequency of the SNP rs183487684 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs183487684 has an effect allele C frequency of 0.0022 and non-effect allele G frequency of 0.9978. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs183487684'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_3056471', 'SNP': 'rs183487684', 'effect_allele': 'C', 'effect_allele_frequency': 0.0022, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.9978}] | general | Select, Calculate | Allele Frequency |
Q3.502 | Q3 | What is the allele frequency of the SNP rs570532932 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs570532932 has an effect allele C frequency of 0.0016 and non-effect allele G frequency of 0.9984. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs570532932'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_5270842', 'SNP': 'rs570532932', 'effect_allele': 'C', 'effect_allele_frequency': 0.0016, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.9984}] | general | Select, Calculate | Allele Frequency |
Q3.1696 | Q3 | What is the allele frequency of the SNP rs183302642 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs183302642 has an effect allele T frequency of 0.0026 and non-effect allele C frequency of 0.9974. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs183302642'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_18049174', 'SNP': 'rs183302642', 'effect_allele': 'T', 'effect_allele_frequency': 0.0026, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.9974}] | general | Select, Calculate | Allele Frequency |
Q3.1721 | Q3 | What is the allele frequency of the SNP rs114172480 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs114172480 has an effect allele C frequency of 0.0039 and non-effect allele T frequency of 0.9961. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs114172480'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_18254447', 'SNP': 'rs114172480', 'effect_allele': 'C', 'effect_allele_frequency': 0.0039, 'non_effect_allele': 'T', 'non_effect_allele_frequency': 0.9961}] | general | Select, Calculate | Allele Frequency |
Q3.1662 | Q3 | What is the allele frequency of the SNP rs73471216 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs73471216 has an effect allele A frequency of 0.0011 and non-effect allele G frequency of 0.9989. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs73471216'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_17737028', 'SNP': 'rs73471216', 'effect_allele': 'A', 'effect_allele_frequency': 0.0011, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.9989}] | general | Select, Calculate | Allele Frequency |
Q3.1639 | Q3 | What is the allele frequency of the SNP rs139499244 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs139499244 has an effect allele T frequency of 0.0257 and non-effect allele C frequency of 0.9743. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs139499244'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_17505018', 'SNP': 'rs139499244', 'effect_allele': 'T', 'effect_allele_frequency': 0.0257, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.9742999999999999}] | general | Select, Calculate | Allele Frequency |
Q3.523 | Q3 | What is the allele frequency of the SNP rs142789910 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs142789910 has an effect allele C frequency of 0.0249 and non-effect allele A frequency of 0.9751. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs142789910'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_5432247', 'SNP': 'rs142789910', 'effect_allele': 'C', 'effect_allele_frequency': 0.0249, 'non_effect_allele': 'A', 'non_effect_allele_frequency': 0.9751}] | general | Select, Calculate | Allele Frequency |
Q3.1985 | Q3 | What is the allele frequency of the SNP rs184595739 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs184595739 has an effect allele T frequency of 0.0062 and non-effect allele C frequency of 0.9938. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs184595739'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_21068843', 'SNP': 'rs184595739', 'effect_allele': 'T', 'effect_allele_frequency': 0.0062, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.9938}] | general | Select, Calculate | Allele Frequency |
Q3.1078 | Q3 | What is the allele frequency of the SNP rs145793190 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs145793190 has an effect allele C frequency of 0.0022 and non-effect allele T frequency of 0.9978. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs145793190'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_11440798', 'SNP': 'rs145793190', 'effect_allele': 'C', 'effect_allele_frequency': 0.0021999999999999, 'non_effect_allele': 'T', 'non_effect_allele_frequency': 0.9978000000000001}] | general | Select, Calculate | Allele Frequency |
Q3.482 | Q3 | What is the allele frequency of the SNP rs192909594 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs192909594 has an effect allele G frequency of 0.0041 and non-effect allele A frequency of 0.9959. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs192909594'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_5010686', 'SNP': 'rs192909594', 'effect_allele': 'G', 'effect_allele_frequency': 0.0040999999999999, 'non_effect_allele': 'A', 'non_effect_allele_frequency': 0.9959000000000001}] | general | Select, Calculate | Allele Frequency |
Q3.160 | Q3 | What is the allele frequency of the SNP rs6541306 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs6541306 has an effect allele T frequency of 0.3567 and non-effect allele C frequency of 0.6433. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs6541306'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_1529376', 'SNP': 'rs6541306', 'effect_allele': 'T', 'effect_allele_frequency': 0.3567, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.6433}] | general | Select, Calculate | Allele Frequency |
Q3.1253 | Q3 | What is the allele frequency of the SNP rs762242218 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs762242218 has an effect allele T frequency of 0.0014 and non-effect allele C frequency of 0.9986. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs762242218'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_13257830', 'SNP': 'rs762242218', 'effect_allele': 'T', 'effect_allele_frequency': 0.0014, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.9986}] | general | Select, Calculate | Allele Frequency |
Q3.1205 | Q3 | What is the allele frequency of the SNP rs77702115 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs77702115 has an effect allele A frequency of 0.0013 and non-effect allele G frequency of 0.9987. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs77702115'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_12839739', 'SNP': 'rs77702115', 'effect_allele': 'A', 'effect_allele_frequency': 0.0013, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.9987}] | general | Select, Calculate | Allele Frequency |
Q3.17 | Q3 | What is the allele frequency of the SNP rs138126448 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs138126448 has an effect allele T frequency of 0.0037 and non-effect allele C frequency of 0.9963. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs138126448'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_283034', 'SNP': 'rs138126448', 'effect_allele': 'T', 'effect_allele_frequency': 0.0037, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.9963}] | general | Select, Calculate | Allele Frequency |
Q3.1550 | Q3 | What is the allele frequency of the SNP rs8004380 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs8004380 has an effect allele A frequency of 0.0009 and non-effect allele G frequency of 0.9991. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs8004380'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_16570871', 'SNP': 'rs8004380', 'effect_allele': 'A', 'effect_allele_frequency': 0.0009, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.9991}] | general | Select, Calculate | Allele Frequency |
Q3.1081 | Q3 | What is the allele frequency of the SNP rs4449823 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs4449823 has an effect allele C frequency of 0.0016 and non-effect allele T frequency of 0.9984. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs4449823'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_11453047', 'SNP': 'rs4449823', 'effect_allele': 'C', 'effect_allele_frequency': 0.0016, 'non_effect_allele': 'T', 'non_effect_allele_frequency': 0.9984}] | general | Select, Calculate | Allele Frequency |
Q3.1972 | Q3 | What is the allele frequency of the SNP rs541526996 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs541526996 has an effect allele T frequency of 0.0008 and non-effect allele G frequency of 0.9992. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs541526996'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_20938217', 'SNP': 'rs541526996', 'effect_allele': 'T', 'effect_allele_frequency': 0.0008, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.9992}] | general | Select, Calculate | Allele Frequency |
Q3.552 | Q3 | What is the allele frequency of the SNP rs746556978 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs746556978 has an effect allele G frequency of 0.0007 and non-effect allele A frequency of 0.9993. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs746556978'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_5729539', 'SNP': 'rs746556978', 'effect_allele': 'G', 'effect_allele_frequency': 0.0007, 'non_effect_allele': 'A', 'non_effect_allele_frequency': 0.9993}] | general | Select, Calculate | Allele Frequency |
Q3.1554 | Q3 | What is the allele frequency of the SNP rs12897201 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs12897201 has an effect allele C frequency of 0.2869 and non-effect allele T frequency of 0.7131. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs12897201'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_16632056', 'SNP': 'rs12897201', 'effect_allele': 'C', 'effect_allele_frequency': 0.2869, 'non_effect_allele': 'T', 'non_effect_allele_frequency': 0.7131000000000001}] | general | Select, Calculate | Allele Frequency |
Q3.665 | Q3 | What is the allele frequency of the SNP rs10940156 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs10940156 has an effect allele A frequency of 0.2527 and non-effect allele G frequency of 0.7473. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs10940156'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_6949297', 'SNP': 'rs10940156', 'effect_allele': 'A', 'effect_allele_frequency': 0.2527, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.7473000000000001}] | general | Select, Calculate | Allele Frequency |
Q3.1626 | Q3 | What is the allele frequency of the SNP rs144057016 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs144057016 has an effect allele T frequency of 0.0004 and non-effect allele C frequency of 0.9996. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs144057016'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_17384998', 'SNP': 'rs144057016', 'effect_allele': 'T', 'effect_allele_frequency': 0.0004, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.9996}] | general | Select, Calculate | Allele Frequency |
Q3.1028 | Q3 | What is the allele frequency of the SNP rs114424632 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs114424632 has an effect allele T frequency of 0.002 and non-effect allele C frequency of 0.998. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs114424632'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_10999244', 'SNP': 'rs114424632', 'effect_allele': 'T', 'effect_allele_frequency': 0.002, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.998}] | general | Select, Calculate | Allele Frequency |
Q3.1994 | Q3 | What is the allele frequency of the SNP rs144586668 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs144586668 has an effect allele G frequency of 0.0081 and non-effect allele A frequency of 0.9919. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs144586668'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_21116190', 'SNP': 'rs144586668', 'effect_allele': 'G', 'effect_allele_frequency': 0.0080999999999999, 'non_effect_allele': 'A', 'non_effect_allele_frequency': 0.9919000000000001}] | general | Select, Calculate | Allele Frequency |
Q3.1519 | Q3 | What is the allele frequency of the SNP rs7997002 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs7997002 has an effect allele A frequency of 0.4631 and non-effect allele C frequency of 0.5369. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs7997002'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_16322140', 'SNP': 'rs7997002', 'effect_allele': 'A', 'effect_allele_frequency': 0.4631, 'non_effect_allele': 'C', 'non_effect_allele_frequency': 0.5368999999999999}] | general | Select, Calculate | Allele Frequency |
Q3.968 | Q3 | What is the allele frequency of the SNP rs571378508 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs571378508 has an effect allele A frequency of 0.0021 and non-effect allele G frequency of 0.9979. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs571378508'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_10391852', 'SNP': 'rs571378508', 'effect_allele': 'A', 'effect_allele_frequency': 0.0021, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.9979}] | general | Select, Calculate | Allele Frequency |
Q3.1883 | Q3 | What is the allele frequency of the SNP rs73080045 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs73080045 has an effect allele G frequency of 0.0811 and non-effect allele A frequency of 0.9189. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs73080045'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_20163150', 'SNP': 'rs73080045', 'effect_allele': 'G', 'effect_allele_frequency': 0.0810999999999999, 'non_effect_allele': 'A', 'non_effect_allele_frequency': 0.9189}] | general | Select, Calculate | Allele Frequency |
Q3.287 | Q3 | What is the allele frequency of the SNP rs74956698 in an Alzheimer's disease study within a European cohort? | According to the largest European genome-wide meta-analysis of Alzheimer's disease (Bellenguez, 2022), single nucleotide polymorphism rs74956698 has an effect allele T frequency of 0.0011 and non-effect allele G frequency of 0.9989. | SELECT UUID, SNP, A1 AS effect_allele, freq AS effect_allele_frequency, A2 AS non_effect_allele, 1 - freq AS non_effect_allele_frequency
FROM `{project_id}.{dataset_name}.AlzheimerDisease_CombinedGeneData_UUID`
WHERE SNP = 'rs74956698'
LIMIT 1 | [{'UUID': 'AD_combo_gene_notext_UUID_2805084', 'SNP': 'rs74956698', 'effect_allele': 'T', 'effect_allele_frequency': 0.0011, 'non_effect_allele': 'G', 'non_effect_allele_frequency': 0.9989}] | general | Select, Calculate | Allele Frequency |
Q34.1943 | Q34 | What are the names of the genes that are targeted by the drug Voclosporin in the treatment of lupus nephritis? | In the context of lupus nephritis, the drug Voclosporin targets the gene protein phosphatase 3 catalytic subunit alpha. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%lupus nephritis%" OR LOWER(efo_term) LIKE "%lupus nephritis%") AND (LOWER(drugName) LIKE "%voclosporin%" OR LOWER(tradeNames_list) LIKE "%voclosporin%" OR LOWER(syns_list) LIKE "%voclosporin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1192227', 'drugName': 'Voclosporin', 'tradeNames_list': "['Lupkynis']", 'syns_list': "['ISA-247', 'ISA247', 'ISATX-247', 'ISATX247', 'LX-211', 'LX211', 'Voclosporin']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Nephritis', 'efo_term': 'lupus nephritis', 'approvedSymbol': 'PPP3CA', 'approvedName': 'protein phosphatase 3 catalytic subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1192239', 'drugName': 'Voclosporin', 'tradeNames_list': "['Lupkynis']", 'syns_list': "['ISA-247', 'ISA247', 'ISATX-247', 'ISATX247', 'LX-211', 'LX211', 'Voclosporin']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lupus Nephritis', 'efo_term': 'lupus nephritis', 'approvedSymbol': 'PPP3CA', 'approvedName': 'protein phosphatase 3 catalytic subunit alpha'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1008 | Q34 | What are the names of the genes that are targeted by the drug Ipratropium Bromide in the treatment of Bronchospasm? | In the context of Bronchospasm, the drug Ipratropium Bromide targets the gene cholinergic receptor muscarinic 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%bronchospasm%" OR LOWER(efo_term) LIKE "%bronchospasm%") AND (LOWER(drugName) LIKE "%ipratropium bromide%" OR LOWER(tradeNames_list) LIKE "%ipratropium bromide%" OR LOWER(syns_list) LIKE "%ipratropium bromide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_857474', 'drugName': 'Ipratropium Bromide', 'tradeNames_list': "['Atrovent', 'Atrovent aerocaps', 'Atrovent fte', 'Atrovent hfaAtrovent udvs', 'Ipratrop', 'Ipratrop steripoule', 'Ipratropium bromideRespontin', 'Rinatec', 'Tropiovent']", 'syns_list': "['Ipratropium bromide', 'Ipratropium bromide anhydrousIpratropium bromide hydrate', 'Ipratropium bromide monohydrateNSC-759613', 'SCH 1000-BR-MONOHYDRATE', 'SCH-1000-BR-']", 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bronchial Spasm', 'efo_term': 'Bronchospasm', 'approvedSymbol': 'CHRM3', 'approvedName': 'cholinergic receptor muscarinic 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.57 | Q34 | What are the names of the genes that are targeted by the drug Lurasidone Hydrochloride in the treatment of bipolar I disorder? | In the context of bipolar I disorder, the drug Lurasidone Hydrochloride targets the gene dopamine receptor D2 and 5-hydroxytryptamine receptor 2A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%bipolar i disorder%" OR LOWER(efo_term) LIKE "%bipolar i disorder%") AND (LOWER(drugName) LIKE "%lurasidone hydrochloride%" OR LOWER(tradeNames_list) LIKE "%lurasidone hydrochloride%" OR LOWER(syns_list) LIKE "%lurasidone hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_197914', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197923', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197926', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197929', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197935', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197938', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197941', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197947', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197950', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197953', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197956', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197962', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197965', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197968', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197971', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197974', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197977', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197980', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197983', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197986', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197989', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197995', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197998', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198001', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198004', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198007', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198013', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198016', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198019', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198022', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198025', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198028', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198031', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198034', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198037', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198040', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198043', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198046', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198049', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198052', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198055', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198058', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198061', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198064', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198067', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198070', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198073', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198076', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198079', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198082', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198085', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198091', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198094', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198097', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198100', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198103', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198106', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198112', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198115', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198118', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198121', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198124', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198127', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198130', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198133', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198136', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198139', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198142', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198145', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198148', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198151', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198154', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198157', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198160', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198163', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198166', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198169', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198172', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198175', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198178', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198181', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198184', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198187', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198190', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198193', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198196', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'HTR2A', 'approvedName': '5-hydroxytryptamine receptor 2A'}, {'UUID': 'DrugTargetsIndication121923_text_198088', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197992', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197944', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197920', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197908', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197902', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197899', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198109', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_198010', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197959', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197932', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197917', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197911', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_197905', 'drugName': 'Lurasidone Hydrochloride', 'tradeNames_list': "['Latuda']", 'syns_list': "['Lurasidone hcl', 'Lurasidone hydrochloride', 'SM-13496']", 'yearOfFirstApproval': 2010, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1439 | Q34 | What are the names of the genes that are targeted by the drug Amlodipine Benzoate in the treatment of hypertension? | In the context of hypertension, the drug Amlodipine Benzoate targets the gene calcium voltage-gated channel subunit alpha1 C, calcium voltage-gated channel subunit alpha1 S, calcium voltage-gated channel subunit alpha1 D and calcium voltage-gated channel subunit alpha1 F. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypertension%" OR LOWER(efo_term) LIKE "%hypertension%") AND (LOWER(drugName) LIKE "%amlodipine benzoate%" OR LOWER(tradeNames_list) LIKE "%amlodipine benzoate%" OR LOWER(syns_list) LIKE "%amlodipine benzoate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1044026', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1044044', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044050', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044056', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044068', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044074', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044080', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044092', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044098', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044104', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044110', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044122', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044128', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044134', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044140', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044146', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044152', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044158', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044164', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044170', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044176', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044182', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F'}, {'UUID': 'DrugTargetsIndication121923_text_1044086', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044038', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1044014', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1044002', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1043996', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1044116', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D'}, {'UUID': 'DrugTargetsIndication121923_text_1044062', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S'}, {'UUID': 'DrugTargetsIndication121923_text_1044032', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1044020', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}, {'UUID': 'DrugTargetsIndication121923_text_1044008', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'syns_list': "['Amlodipine benzoate']", 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1129 | Q34 | What are the names of the genes that are targeted by the drug Cobimetinib in the treatment of neoplasm? | In the context of neoplasm, the drug Cobimetinib targets the gene mitogen-activated protein kinase kinase 2 and mitogen-activated protein kinase kinase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%cobimetinib%" OR LOWER(tradeNames_list) LIKE "%cobimetinib%" OR LOWER(syns_list) LIKE "%cobimetinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_927356', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927631', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927678', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927194', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927425', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927539', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927287', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927516', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927447', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927585', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927517', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927632', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927217', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927655', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927424', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927701', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927723', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927700', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927378', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927263', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927563', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927470', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927562', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927402', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927240', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927494', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927609', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927677', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927401', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927333', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927586', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927379', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927332', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927309', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927264', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927608', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927355', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927724', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927654', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927493', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927310', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927540', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927286', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927241', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927448', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927195', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927471', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927218', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927193', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927400', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927331', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927653', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927676', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927699', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927630', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927216', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927722', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927262', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927354', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927285', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927584', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927423', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927446', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927469', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927607', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927377', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927492', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927239', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927515', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927308', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927538', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927561', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927342', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927395', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927343', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927347', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Gallbladder Neoplasms', 'efo_term': 'gallbladder carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927348', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927411', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927412', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927416', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Gallbladder Neoplasms', 'efo_term': 'gallbladder carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927458', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927417', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927434', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927439', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Gallbladder Neoplasms', 'efo_term': 'gallbladder carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927418', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927182', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927273', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927435', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927349', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927274', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927278', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Gallbladder Neoplasms', 'efo_term': 'gallbladder carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927186', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Gallbladder Neoplasms', 'efo_term': 'gallbladder carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927279', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927440', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927457', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K1', 'approvedName': 'mitogen-activated protein kinase kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_927280', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927227', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927228', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927441', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Ovarian Neoplasms', 'efo_term': 'ovarian cancer', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}, {'UUID': 'DrugTargetsIndication121923_text_927232', 'drugName': 'Cobimetinib', 'tradeNames_list': "['Cotellic']", 'syns_list': "['Cobimetinib', 'GDC-0973', 'Gdc 0623', 'Gdc 0973', 'Gdc-0623', 'RG 7420RG-7420', 'RG7420', 'Rg-7420', 'Rg-7421', 'XL-518', 'Xl 518', 'Xl518']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 2.0, 'mesh_heading': 'Gallbladder Neoplasms', 'efo_term': 'gallbladder carcinoma', 'approvedSymbol': 'MAP2K2', 'approvedName': 'mitogen-activated protein kinase kinase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.875 | Q34 | What are the names of the genes that are targeted by the drug Diclofenac Sodium in the treatment of pain? | In the context of pain, the drug Diclofenac Sodium targets the gene prostaglandin-endoperoxide synthase 2 and prostaglandin-endoperoxide synthase 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pain%" OR LOWER(efo_term) LIKE "%pain%") AND (LOWER(drugName) LIKE "%diclofenac sodium%" OR LOWER(tradeNames_list) LIKE "%diclofenac sodium%" OR LOWER(syns_list) LIKE "%diclofenac sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_836631', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836865', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836487', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836541', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836055', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836145', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836379', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836847', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836595', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836613', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836289', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836901', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836667', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836307', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836433', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836163', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836325', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836685', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836127', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836883', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836649', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836811', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836721', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836829', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836739', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836073', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836703', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836577', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836505', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836343', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836253', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836217', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836559', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836469', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836757', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836109', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836919', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836271', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836397', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836199', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836451', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836415', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836037', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836523', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836937', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836793', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836361', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836235', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836181', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836955', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836775', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836091', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Pain', 'efo_term': 'pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836169', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836331', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836835', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836349', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836097', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836187', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836889', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836817', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836619', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836691', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836403', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836907', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836367', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836871', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836421', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836025', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836223', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836583', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836457', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836655', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836241', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836475', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836673', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836547', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836133', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836493', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836727', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836763', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836781', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836043', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836259', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836511', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836439', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836709', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836529', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836079', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836277', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836115', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836745', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836151', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836637', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836565', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836295', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836799', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836601', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836853', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1'}, {'UUID': 'DrugTargetsIndication121923_text_836313', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}, {'UUID': 'DrugTargetsIndication121923_text_836385', 'drugName': 'Diclofenac Sodium', 'tradeNames_list': "['Acoflam', 'Acoflam ret', 'Acoflam sr', 'Arthronac', 'Arthrotec 50Arthrotec 75', 'Closteril 100', 'Defanac', 'Defanac retard', 'Defanac srDexomon ret', 'Dexomon sr', 'Diclofenac sodium', 'DicloflexDicloflex ret', 'Dicloflex sr', 'Diclomax ret', 'Diclomax srDiclotard 100 mr', 'Diclotard 75 mr', 'Diclovol', 'Diclovol retDiclovol sr', 'Diclozip 25', 'Diclozip 50', 'Difenor xl', 'Digenac xl 100Dyloject', 'Econac', 'Econac sr', 'Econac xl', 'Enstar sr', 'Enstar xlEnzed', 'Fenactol', 'Fenactol ret', 'Fenactol sr', 'Flamatak mr', 'FlamraseFlamrase sr', 'Flexotard mr', 'Isclofen', 'Lofensaid 25', 'Lofensaid 50Lofensaid ret 100', 'Lofensaid ret 75', 'Masidemen', 'Misofen', 'MobigelMobigel paineze', 'Motifene', 'Pennsaid', 'Rheumatac ret 75', 'RhumalganRhumalgan cr 100', 'Rhumalgan cr 75', 'Rhumalgan sr', 'Rhumalgan xlSlofenac', 'Solaraze', 'Valdic 100 ret', 'Valdic 75 ret', 'ValenacVolraman', 'Volsaid ret 100', 'Volsaid ret 75', 'VoltarenVoltaren arthritis pain', 'Voltaren emulgel', 'Voltaren ret', 'Voltaren-xrVoltarene', 'Voltarene emulgel', 'Voltarene l.p.', 'Voltarene retVoltarol', 'Voltarol 12 hour emulgel p', 'Voltarol activeVoltarol emulgel', 'Voltarol emulgel p', 'Voltarol gel patchVoltarol ophtha', 'Voltarol pain-eze emulgel', 'Voltarol retVoltarol sr']", 'syns_list': "['Abitren', 'Benfofen', 'Dealgic', 'Deflamat', 'DelphinacDiclofenac diethylamine', 'Diclofenac diethylamine saltDiclofenac diethylammonium', 'Diclofenac diethylammonium saltDiclofenac sod', 'Diclofenac sodium', 'Diclofenac sodium salt', 'DiclomaxDiclophenac sodium', 'Diclophlogont', 'Dicloreum', 'Duravolten', 'EcofenacEffekton', 'GP 45840', 'GP-45840', 'Lexobene', 'NSC-756725', 'NeriodinNovapirina', 'Primofenac', 'Prophenatin', 'Rewodina', 'Sodium diclofenacVoldal', 'Xenid']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Low Back Pain', 'efo_term': 'Low back pain', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.710 | Q34 | What are the names of the genes that are targeted by the drug Nilotinib in the treatment of neoplasm? | In the context of neoplasm, the drug Nilotinib targets the gene ABL proto-oncogene 1, non-receptor tyrosine kinase and BCR activator of RhoGEF and GTPase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%nilotinib%" OR LOWER(tradeNames_list) LIKE "%nilotinib%" OR LOWER(syns_list) LIKE "%nilotinib%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_746682', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746057', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746282', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746456', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746806', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746931', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746982', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745957', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746082', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746156', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746332', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746481', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746532', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746782', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746756', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746831', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746832', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746981', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746932', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747007', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747031', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745907', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745982', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746006', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746132', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746106', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746182', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746432', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746306', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746381', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746382', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746531', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746482', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746557', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746581', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746882', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746706', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746781', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746757', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746881', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746807', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746857', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746856', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747081', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746907', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746957', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746956', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747057', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747006', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747056', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747032', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745882', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745932', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745931', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746032', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745981', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746031', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746232', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746081', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746131', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746107', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746231', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746157', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746207', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746206', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746632', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746281', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746331', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746307', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746431', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746357', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746407', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746406', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746631', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746457', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746507', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746506', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746607', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746556', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746606', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746582', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747082', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746681', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746731', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746707', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747107', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_747106', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746656', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746256', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746056', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745956', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745906', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_745881', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746007', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746181', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746356', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746732', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746906', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746257', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}, {'UUID': 'DrugTargetsIndication121923_text_746657', 'drugName': 'Nilotinib', 'tradeNames_list': "['Tasigna']", 'syns_list': "['AMN 107', 'AMN-107', 'AMN107', 'NSC-747599', 'Nilotinib']", 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.589 | Q34 | What are the names of the genes that are targeted by the drug Carbamazepine in the treatment of bipolar I disorder? | In the context of bipolar I disorder, the drug Carbamazepine targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%bipolar i disorder%" OR LOWER(efo_term) LIKE "%bipolar i disorder%") AND (LOWER(drugName) LIKE "%carbamazepine%" OR LOWER(tradeNames_list) LIKE "%carbamazepine%" OR LOWER(syns_list) LIKE "%carbamazepine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_650986', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_651034', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_651050', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_651066', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_651098', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651114', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651130', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651162', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651178', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651194', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651210', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651242', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651258', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651274', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651290', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651306', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651322', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651338', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651354', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651370', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651386', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651418', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651434', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651450', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651466', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651482', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651514', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651530', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651546', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651562', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651578', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651594', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651610', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651626', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651642', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651658', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651674', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651690', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651706', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651722', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651738', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651754', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651770', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN2A', 'approvedName': 'sodium voltage-gated channel alpha subunit 2'}, {'UUID': 'DrugTargetsIndication121923_text_651786', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_651802', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_651818', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_651834', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_651850', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_651866', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_651882', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_651898', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_651930', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_651946', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_651962', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_651978', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_651994', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_652010', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_652042', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_652058', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_652074', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_652090', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_652106', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_652122', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_652138', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652154', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652170', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652186', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652202', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652218', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652234', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652250', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652266', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652282', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652298', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN11A', 'approvedName': 'sodium voltage-gated channel alpha subunit 11'}, {'UUID': 'DrugTargetsIndication121923_text_652314', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_652330', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_652346', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_652362', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_652378', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_652394', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_652410', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_652426', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_652442', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_652458', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_652474', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN8A', 'approvedName': 'sodium voltage-gated channel alpha subunit 8'}, {'UUID': 'DrugTargetsIndication121923_text_652490', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN10A', 'approvedName': 'sodium voltage-gated channel alpha subunit 10'}, {'UUID': 'DrugTargetsIndication121923_text_651914', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN9A', 'approvedName': 'sodium voltage-gated channel alpha subunit 9'}, {'UUID': 'DrugTargetsIndication121923_text_651402', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4'}, {'UUID': 'DrugTargetsIndication121923_text_651146', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651018', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_650954', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_650922', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_650906', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_652026', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN3A', 'approvedName': 'sodium voltage-gated channel alpha subunit 3'}, {'UUID': 'DrugTargetsIndication121923_text_651498', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN7A', 'approvedName': 'sodium voltage-gated channel alpha subunit 7'}, {'UUID': 'DrugTargetsIndication121923_text_651226', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651082', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_651002', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_650970', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_650938', 'drugName': 'Carbamazepine', 'tradeNames_list': "['Arbil mr', 'Carbagen sr', 'Carbamazepine', 'Carbatrol', 'Carnexiv', 'EpimazEpimaz ret', 'Epitol', 'Equetro', 'Sirtal ret', 'Tegretol', 'Tegretol XrTegretol chewtab', 'Tegretol prolonged release', 'Tegretol-xr', 'TerilTeril ret', 'Timonil 200 ret', 'Timonil 400 ret']", 'syns_list': "['Biston', 'Carbamazepine', 'Carbamazepine anhydrousCarbamazepine extended release', 'Carbamazepinum', 'Finlepsin', 'G-32883GEIGY 32883', 'Karbamazepin', 'Karbelex', 'NSC-169864', 'NeurotolNeurotop', 'Sirtal', 'Stazepine', 'Tegretal', 'Telesmin', 'Timonil']", 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1782 | Q34 | What are the names of the genes that are targeted by the drug Zoledronic Acid in the treatment of bone disease? | In the context of bone disease, the drug Zoledronic Acid targets the gene farnesyl diphosphate synthase. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%bone disease%" OR LOWER(efo_term) LIKE "%bone disease%") AND (LOWER(drugName) LIKE "%zoledronic acid%" OR LOWER(tradeNames_list) LIKE "%zoledronic acid%" OR LOWER(syns_list) LIKE "%zoledronic acid%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1099769', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100154', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099934', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099824', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099714', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100209', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099989', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099879', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099659', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100044', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099604', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100099', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bone Diseases', 'efo_term': 'bone disease', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099909', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Bone Diseases, Metabolic', 'efo_term': 'Osteopenia', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099579', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Bone Diseases, Metabolic', 'efo_term': 'Osteopenia', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099744', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Bone Diseases, Metabolic', 'efo_term': 'Osteopenia', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099799', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Bone Diseases, Metabolic', 'efo_term': 'Osteopenia', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100019', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Bone Diseases, Metabolic', 'efo_term': 'Osteopenia', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100074', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Bone Diseases, Metabolic', 'efo_term': 'Osteopenia', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099689', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Bone Diseases, Metabolic', 'efo_term': 'Osteopenia', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099854', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Bone Diseases, Metabolic', 'efo_term': 'Osteopenia', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100129', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Bone Diseases, Metabolic', 'efo_term': 'Osteopenia', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1100184', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Bone Diseases, Metabolic', 'efo_term': 'Osteopenia', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099634', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Bone Diseases, Metabolic', 'efo_term': 'Osteopenia', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}, {'UUID': 'DrugTargetsIndication121923_text_1099964', 'drugName': 'Zoledronic Acid', 'tradeNames_list': "['Aclasta', 'Reclast', 'Zerlinda', 'Zoledronic acid', 'Zometa']", 'syns_list': "['AK-156', 'Anhydrous zoledronic acid', 'CGP 42446', 'CGP-42446', 'CGP-42446ANSC-721517', 'Zoladrona acid mylan', 'Zoledronate', 'Zoledronate hydrateZoledronic', 'Zoledronic acid', 'Zoledronic acid accordZoledronic acid anhydrous', 'Zoledronic acid hydrateZoledronic acid medac', 'Zoledronic acid monohydrateZoledronic acid teva', 'Zometa']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 3.0, 'mesh_heading': 'Bone Diseases, Metabolic', 'efo_term': 'Osteopenia', 'approvedSymbol': 'FDPS', 'approvedName': 'farnesyl diphosphate synthase'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.985 | Q34 | What are the names of the genes that are targeted by the drug Trilaciclib Dihydrochloride in the treatment of small cell lung carcinoma? | In the context of small cell lung carcinoma, the drug Trilaciclib Dihydrochloride targets the gene cyclin dependent kinase 4 and cyclin dependent kinase 6. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%small cell lung carcinoma%" OR LOWER(efo_term) LIKE "%small cell lung carcinoma%") AND (LOWER(drugName) LIKE "%trilaciclib dihydrochloride%" OR LOWER(tradeNames_list) LIKE "%trilaciclib dihydrochloride%" OR LOWER(syns_list) LIKE "%trilaciclib dihydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_851297', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'syns_list': "['Trilaciclib dihydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851300', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'syns_list': "['Trilaciclib dihydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851301', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'syns_list': "['Trilaciclib dihydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851302', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'syns_list': "['Trilaciclib dihydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851304', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'syns_list': "['Trilaciclib dihydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_851305', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'syns_list': "['Trilaciclib dihydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_851306', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'syns_list': "['Trilaciclib dihydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_851308', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'syns_list': "['Trilaciclib dihydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_851309', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'syns_list': "['Trilaciclib dihydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_851310', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'syns_list': "['Trilaciclib dihydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_851311', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'syns_list': "['Trilaciclib dihydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_851313', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'syns_list': "['Trilaciclib dihydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_851314', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'syns_list': "['Trilaciclib dihydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_851315', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'syns_list': "['Trilaciclib dihydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_851307', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'syns_list': "['Trilaciclib dihydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_851299', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'syns_list': "['Trilaciclib dihydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851295', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'syns_list': "['Trilaciclib dihydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851293', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'syns_list': "['Trilaciclib dihydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851292', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'syns_list': "['Trilaciclib dihydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851312', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'syns_list': "['Trilaciclib dihydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma', 'approvedSymbol': 'CDK6', 'approvedName': 'cyclin dependent kinase 6'}, {'UUID': 'DrugTargetsIndication121923_text_851303', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'syns_list': "['Trilaciclib dihydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851298', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'syns_list': "['Trilaciclib dihydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851296', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'syns_list': "['Trilaciclib dihydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}, {'UUID': 'DrugTargetsIndication121923_text_851294', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_list': "['Cosela']", 'syns_list': "['Trilaciclib dihydrochloride']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Small Cell Lung Carcinoma', 'efo_term': 'small cell lung carcinoma', 'approvedSymbol': 'CDK4', 'approvedName': 'cyclin dependent kinase 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.443 | Q34 | What are the names of the genes that are targeted by the drug Epinephrine in the treatment of glaucoma? | In the context of glaucoma, the drug Epinephrine targets the gene adrenoceptor alpha 1A, adrenoceptor beta 2, adrenoceptor beta 1, adrenoceptor beta 3, adrenoceptor alpha 1D, adrenoceptor alpha 1B, adrenoceptor alpha 2A, adrenoceptor alpha 2C and adrenoceptor alpha 2B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%glaucoma%" OR LOWER(efo_term) LIKE "%glaucoma%") AND (LOWER(drugName) LIKE "%epinephrine%" OR LOWER(tradeNames_list) LIKE "%epinephrine%" OR LOWER(syns_list) LIKE "%epinephrine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_361089', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361248', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361301', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361354', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361460', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361513', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361566', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361672', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361725', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361778', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361831', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361937', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361990', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362043', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362096', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362149', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362202', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362255', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362308', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362361', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362414', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362520', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362573', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362626', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362679', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362732', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362838', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362891', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362944', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362997', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363050', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363103', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363156', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363209', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363262', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363315', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363368', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363421', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363474', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363527', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363580', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363633', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363686', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363739', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363792', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363845', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363898', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_363951', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364004', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364057', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364110', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364216', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364269', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364322', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364375', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364428', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364481', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364587', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364640', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364693', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364746', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364799', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364852', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364905', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364958', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365011', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365064', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365117', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365170', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365223', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365276', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365329', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365382', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365435', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365488', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365541', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365594', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365647', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365700', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365753', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365806', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365859', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365912', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_365965', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_366018', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_366071', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364163', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362467', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361619', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361195', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360983', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360877', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360824', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_364534', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_362785', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361884', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361407', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361142', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_361036', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}, {'UUID': 'DrugTargetsIndication121923_text_360930', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'syns_list': "['(-)-(r)-epinephrine', '(-)-epinephrine', 'Adrenaline', 'AdrenalinumEpinephrine', 'Epinephrine hcl', 'Epinephrine hydrochlorideEpinephrinum', 'Glauposine', 'L-epinephrine hydrochlorideLevo-methylaminoethanolcatechol', 'NSC-62786', 'NephridineRacepinefrine hydrochloride, (r)-', 'Racepinefrine, (r)-Sus-phrine sulphite-free', 'Susphrine', 'Tonogen', 'Twinject']", 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Glaucoma', 'efo_term': 'glaucoma', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1873 | Q34 | What are the names of the genes that are targeted by the drug Lenalidomide in the treatment of anemia? | In the context of anemia, the drug Lenalidomide targets the gene cereblon, damage specific DNA binding protein 1, cullin 4A and ring-box 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%anemia%" OR LOWER(efo_term) LIKE "%anemia%") AND (LOWER(drugName) LIKE "%lenalidomide%" OR LOWER(tradeNames_list) LIKE "%lenalidomide%" OR LOWER(syns_list) LIKE "%lenalidomide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1105913', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106085', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106087', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106172', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106259', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106261', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106346', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106433', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106435', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106520', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106522', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106609', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106694', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106696', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106781', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106783', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106868', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106870', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106955', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106957', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107042', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107129', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107131', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107216', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107218', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107303', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107390', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107392', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107477', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107479', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107564', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107566', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107651', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107653', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107738', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107740', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107825', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107827', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107912', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107914', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107999', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108001', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108086', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108088', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108173', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108175', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108260', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108262', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108347', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108349', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108434', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108521', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108523', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108608', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108610', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108695', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108697', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108784', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108869', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108871', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108956', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108958', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109043', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109045', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109130', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109132', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109217', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109219', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109304', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109306', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109391', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109393', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109478', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109480', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109565', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109567', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109652', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109654', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109739', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109741', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109826', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109828', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109913', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1109915', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1110000', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1110002', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108436', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107044', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106348', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106000', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1105826', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1105739', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1105737', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1108782', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1107305', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106607', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1106174', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1105998', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1105911', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}, {'UUID': 'DrugTargetsIndication121923_text_1105824', 'drugName': 'Lenalidomide', 'tradeNames_list': "['Revlimid']", 'syns_list': "['CC-5013', 'CDC-501', 'Lenalidomide', 'NSC-747972', 'SYP-1512']", 'yearOfFirstApproval': 2005, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia', 'efo_term': 'anemia (phenotype)', 'approvedSymbol': 'CRBN', 'approvedName': 'cereblon'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.70 | Q34 | What are the names of the genes that are targeted by the drug Cariprazine Hydrochloride in the treatment of bipolar disorder? | In the context of bipolar disorder, the drug Cariprazine Hydrochloride targets the gene dopamine receptor D2 and dopamine receptor D3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%bipolar disorder%" OR LOWER(efo_term) LIKE "%bipolar disorder%") AND (LOWER(drugName) LIKE "%cariprazine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%cariprazine hydrochloride%" OR LOWER(syns_list) LIKE "%cariprazine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_199881', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199886', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199887', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199889', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199892', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199893', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199895', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199898', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199899', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199901', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199902', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199905', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199907', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199908', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199910', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199911', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199913', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199914', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199916', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199917', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199919', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199922', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199923', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199925', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199926', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199928', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199931', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199932', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199934', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199935', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199937', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199938', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199940', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199941', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199943', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199944', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199946', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199947', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199949', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199950', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199952', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199953', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199955', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199956', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199958', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199959', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199961', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199962', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199964', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199965', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199967', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199970', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199971', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199973', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199974', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199976', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199977', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199980', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199982', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199983', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199985', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199986', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199988', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199989', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199991', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199992', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199994', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199995', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199997', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199998', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200000', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200001', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200003', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200004', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200006', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200007', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200009', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200010', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200012', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200013', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200015', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200016', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200018', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200019', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200021', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200022', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199968', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199920', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199896', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199884', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199878', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199875', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199874', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199979', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199929', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199904', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199890', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar I disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199883', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199880', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199877', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Bipolar Disorder', 'efo_term': 'bipolar disorder', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1915 | Q34 | What are the names of the genes that are targeted by the drug Teduglutide in the treatment of primary short bowel syndrome? | In the context of primary short bowel syndrome, the drug Teduglutide targets the gene glucagon like peptide 2 receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%primary short bowel syndrome%" OR LOWER(efo_term) LIKE "%primary short bowel syndrome%") AND (LOWER(drugName) LIKE "%teduglutide%" OR LOWER(tradeNames_list) LIKE "%teduglutide%" OR LOWER(syns_list) LIKE "%teduglutide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1149494', 'drugName': 'Teduglutide', 'tradeNames_list': "['Gattex kit']", 'syns_list': "['ALX 0600', 'ALX-0600', 'Gattex', 'Revestive', 'TeduglutideTeduglutide (rdna origin)', 'Teduglutide recombinant']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Short Bowel Syndrome', 'efo_term': 'primary short bowel syndrome', 'approvedSymbol': 'GLP2R', 'approvedName': 'glucagon like peptide 2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149458', 'drugName': 'Teduglutide', 'tradeNames_list': "['Gattex kit']", 'syns_list': "['ALX 0600', 'ALX-0600', 'Gattex', 'Revestive', 'TeduglutideTeduglutide (rdna origin)', 'Teduglutide recombinant']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Short Bowel Syndrome', 'efo_term': 'primary short bowel syndrome', 'approvedSymbol': 'GLP2R', 'approvedName': 'glucagon like peptide 2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149449', 'drugName': 'Teduglutide', 'tradeNames_list': "['Gattex kit']", 'syns_list': "['ALX 0600', 'ALX-0600', 'Gattex', 'Revestive', 'TeduglutideTeduglutide (rdna origin)', 'Teduglutide recombinant']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Short Bowel Syndrome', 'efo_term': 'primary short bowel syndrome', 'approvedSymbol': 'GLP2R', 'approvedName': 'glucagon like peptide 2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149476', 'drugName': 'Teduglutide', 'tradeNames_list': "['Gattex kit']", 'syns_list': "['ALX 0600', 'ALX-0600', 'Gattex', 'Revestive', 'TeduglutideTeduglutide (rdna origin)', 'Teduglutide recombinant']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Short Bowel Syndrome', 'efo_term': 'primary short bowel syndrome', 'approvedSymbol': 'GLP2R', 'approvedName': 'glucagon like peptide 2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149485', 'drugName': 'Teduglutide', 'tradeNames_list': "['Gattex kit']", 'syns_list': "['ALX 0600', 'ALX-0600', 'Gattex', 'Revestive', 'TeduglutideTeduglutide (rdna origin)', 'Teduglutide recombinant']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Short Bowel Syndrome', 'efo_term': 'primary short bowel syndrome', 'approvedSymbol': 'GLP2R', 'approvedName': 'glucagon like peptide 2 receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149467', 'drugName': 'Teduglutide', 'tradeNames_list': "['Gattex kit']", 'syns_list': "['ALX 0600', 'ALX-0600', 'Gattex', 'Revestive', 'TeduglutideTeduglutide (rdna origin)', 'Teduglutide recombinant']", 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Short Bowel Syndrome', 'efo_term': 'primary short bowel syndrome', 'approvedSymbol': 'GLP2R', 'approvedName': 'glucagon like peptide 2 receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.72 | Q34 | What are the names of the genes that are targeted by the drug Cariprazine Hydrochloride in the treatment of schizophrenia? | In the context of schizophrenia, the drug Cariprazine Hydrochloride targets the gene dopamine receptor D2 and dopamine receptor D3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%schizophrenia%" OR LOWER(efo_term) LIKE "%schizophrenia%") AND (LOWER(drugName) LIKE "%cariprazine hydrochloride%" OR LOWER(tradeNames_list) LIKE "%cariprazine hydrochloride%" OR LOWER(syns_list) LIKE "%cariprazine hydrochloride%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_199891', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199900', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199903', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199906', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199912', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199915', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199918', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199924', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199927', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199930', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199933', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199939', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199942', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199945', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199948', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199951', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199954', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199957', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199960', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199963', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199966', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199972', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199975', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199978', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199981', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199984', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199990', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199993', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199996', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199999', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200002', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200005', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200008', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200011', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200014', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200017', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200020', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200023', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200026', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200029', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200032', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200035', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200038', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200041', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200044', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200047', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200050', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200053', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200056', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200059', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200062', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200068', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200071', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200074', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200077', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_200065', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199969', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199897', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199885', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199879', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199876', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199921', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199987', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD3', 'approvedName': 'dopamine receptor D3'}, {'UUID': 'DrugTargetsIndication121923_text_199936', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199909', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199894', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199888', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}, {'UUID': 'DrugTargetsIndication121923_text_199882', 'drugName': 'Cariprazine Hydrochloride', 'tradeNames_list': "['Vraylar']", 'syns_list': "['Cariprazine hcl', 'Cariprazine hydrochloride', 'RGH-188 HCL']", 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Schizophrenia', 'efo_term': 'schizophrenia', 'approvedSymbol': 'DRD2', 'approvedName': 'dopamine receptor D2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1759 | Q34 | What are the names of the genes that are targeted by the drug Lansoprazole in the treatment of gastroesophageal reflux disease? | In the context of gastroesophageal reflux disease, the drug Lansoprazole targets the gene ATPase H+/K+ transporting subunit alpha and ATPase H+/K+ transporting subunit beta. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%gastroesophageal reflux disease%" OR LOWER(efo_term) LIKE "%gastroesophageal reflux disease%") AND (LOWER(drugName) LIKE "%lansoprazole%" OR LOWER(tradeNames_list) LIKE "%lansoprazole%" OR LOWER(syns_list) LIKE "%lansoprazole%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1098431', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098455', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098463', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098471', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098487', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098495', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098503', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098519', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098527', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098535', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098543', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098559', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098567', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098575', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098583', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098591', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098599', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098607', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098615', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098623', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098631', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098647', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098655', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098663', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098671', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098679', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098695', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098703', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098711', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098719', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098727', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098735', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098743', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098751', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098759', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098767', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098775', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098783', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098791', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098799', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098807', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098815', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098823', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098831', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098839', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098847', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098855', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098863', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098871', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098879', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098887', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098903', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098911', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098919', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098927', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098935', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098943', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098959', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098967', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098975', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098983', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098991', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098999', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099007', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099015', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099023', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099031', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099039', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099047', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099055', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099063', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099071', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099079', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099087', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099095', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099103', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099111', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099119', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099127', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099135', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099143', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099151', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099159', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099167', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099175', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1099183', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098895', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098639', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098511', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098447', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098416', 'drugName': 'Lansoprazole', 'tradeNames_list': "['Lansoprazole', 'Opiren', 'Prevacid', 'Prevacid 24 hrPrevacid Delayed Release', 'Prevacid Solutab', 'Prevacid iv', 'Zoton']", 'syns_list': "['A-65006', 'AG-1749', 'Agopton', 'Lansoprazole', 'Lansox', 'LanzoprazoleLanzor', 'Limpidex', 'NSC-758638', 'Ogast', 'Ogastoro', 'Prevonco', 'Takepron']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098368', 'drugName': 'Lansoprazole', 'tradeNames_list': "['Lansoprazole', 'Opiren', 'Prevacid', 'Prevacid 24 hrPrevacid Delayed Release', 'Prevacid Solutab', 'Prevacid iv', 'Zoton']", 'syns_list': "['A-65006', 'AG-1749', 'Agopton', 'Lansoprazole', 'Lansox', 'LanzoprazoleLanzor', 'Limpidex', 'NSC-758638', 'Ogast', 'Ogastoro', 'Prevonco', 'Takepron']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098344', 'drugName': 'Lansoprazole', 'tradeNames_list': "['Lansoprazole', 'Opiren', 'Prevacid', 'Prevacid 24 hrPrevacid Delayed Release', 'Prevacid Solutab', 'Prevacid iv', 'Zoton']", 'syns_list': "['A-65006', 'AG-1749', 'Agopton', 'Lansoprazole', 'Lansox', 'LanzoprazoleLanzor', 'Limpidex', 'NSC-758638', 'Ogast', 'Ogastoro', 'Prevonco', 'Takepron']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098951', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1098687', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098551', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098479', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098439', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098423', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'syns_list': "['(r)-lansoprazole', 'Dexlansoprazole', 'Kapidex', 'Lansoprazole r-formLansoprazole, (r)-', 'NSC-758710', 'T-168390', 'TAK-390']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1098392', 'drugName': 'Lansoprazole', 'tradeNames_list': "['Lansoprazole', 'Opiren', 'Prevacid', 'Prevacid 24 hrPrevacid Delayed Release', 'Prevacid Solutab', 'Prevacid iv', 'Zoton']", 'syns_list': "['A-65006', 'AG-1749', 'Agopton', 'Lansoprazole', 'Lansox', 'LanzoprazoleLanzor', 'Limpidex', 'NSC-758638', 'Ogast', 'Ogastoro', 'Prevonco', 'Takepron']", 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.604 | Q34 | What are the names of the genes that are targeted by the drug Eslicarbazepine Acetate in the treatment of Seizure? | In the context of Seizure, the drug Eslicarbazepine Acetate targets the gene sodium voltage-gated channel alpha subunit 1, sodium voltage-gated channel alpha subunit 5, sodium voltage-gated channel alpha subunit 4, sodium voltage-gated channel alpha subunit 7, sodium voltage-gated channel alpha subunit 2, sodium voltage-gated channel alpha subunit 9, sodium voltage-gated channel alpha subunit 3, sodium voltage-gated channel alpha subunit 11, sodium voltage-gated channel alpha subunit 8 and sodium voltage-gated channel alpha subunit 10. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%seizure%" OR LOWER(efo_term) LIKE "%seizure%") AND (LOWER(drugName) LIKE "%eslicarbazepine acetate%" OR LOWER(tradeNames_list) LIKE "%eslicarbazepine acetate%" OR LOWER(syns_list) LIKE "%eslicarbazepine acetate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_656750', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_656780', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_656790', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_656800', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_656820', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_656830', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_656840', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_656860', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_656870', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_656880', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_656890', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_656910', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_656920', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_656930', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_656940', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_656950', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_656960', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_656970', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_656980', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_656990', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_657000', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_657020', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_657030', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_657040', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_657050', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_657060', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_657080', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_657090', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_657100', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_657110', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_657120', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_657130', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_657140', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_657150', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_657160', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_657170', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_657180', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_657190', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_657200', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_657210', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_657220', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_657230', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_657240', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_657250', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_657260', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_657270', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_657280', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_657290', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_657300', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657310', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657320', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657340', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657350', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657360', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657370', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657380', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657390', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657410', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657420', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657430', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657440', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657450', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657460', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657470', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657480', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657490', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657500', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657510', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657520', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657530', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657540', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657550', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657560', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657570', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657580', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657590', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657600', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657610', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657620', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657630', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657640', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657650', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657660', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657670', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657680', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657690', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657330', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657010', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_656850', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_656770', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_656730', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_656710', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_656700', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_657400', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5'}, {'UUID': 'DrugTargetsIndication121923_text_657070', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_656900', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_656810', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_656760', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_656740', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}, {'UUID': 'DrugTargetsIndication121923_text_656720', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_list': "['Aptiom', 'Erelib', 'Pazzul', 'Stedesa', 'Zebinix']", 'syns_list': "['BIA 2-093', 'BIA-2-093', 'BIA-2093', 'Eslicarbazepine acetateSEP - 0002093', 'SEP-0002093']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Seizures', 'efo_term': 'Seizure', 'approvedSymbol': 'SCN1A', 'approvedName': 'sodium voltage-gated channel alpha subunit 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1794 | Q34 | What are the names of the genes that are targeted by the drug Nizatidine in the treatment of Peptic ulcer? | In the context of Peptic ulcer, the drug Nizatidine targets the gene histamine receptor H2. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%peptic ulcer%" OR LOWER(efo_term) LIKE "%peptic ulcer%") AND (LOWER(drugName) LIKE "%nizatidine%" OR LOWER(tradeNames_list) LIKE "%nizatidine%" OR LOWER(syns_list) LIKE "%nizatidine%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1100308', 'drugName': 'Nizatidine', 'tradeNames_list': "['Axid', 'Axid ar', 'Nizatidine', 'Zinga 150', 'Zinga 300']", 'syns_list': "['Acinon', 'LY 139037', 'LY-139037', 'NSC-759289', 'Nizatidine']", 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer', 'approvedSymbol': 'HRH2', 'approvedName': 'histamine receptor H2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1793 | Q34 | What are the names of the genes that are targeted by the drug Dantrolene Sodium in the treatment of multiple sclerosis? | In the context of multiple sclerosis, the drug Dantrolene Sodium targets the gene ryanodine receptor 3 and ryanodine receptor 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%multiple sclerosis%" OR LOWER(efo_term) LIKE "%multiple sclerosis%") AND (LOWER(drugName) LIKE "%dantrolene sodium%" OR LOWER(tradeNames_list) LIKE "%dantrolene sodium%" OR LOWER(syns_list) LIKE "%dantrolene sodium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1100268', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'RYR1', 'approvedName': 'ryanodine receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1100295', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'RYR1', 'approvedName': 'ryanodine receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1100304', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'RYR1', 'approvedName': 'ryanodine receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1100286', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'RYR1', 'approvedName': 'ryanodine receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1100232', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'RYR3', 'approvedName': 'ryanodine receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1100223', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'RYR3', 'approvedName': 'ryanodine receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1100250', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'RYR3', 'approvedName': 'ryanodine receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1100277', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'RYR1', 'approvedName': 'ryanodine receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_1100259', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'RYR3', 'approvedName': 'ryanodine receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_1100241', 'drugName': 'Dantrolene Sodium', 'tradeNames_list': "['Dantrium', 'Dantrolene sodium', 'Revonto', 'Ryanodex']", 'syns_list': "['Dantamacrin', 'Dantrolen', 'Dantrolene sodiumDantrolene sodium heptahydrate', 'Dantrolene sodium hydrateDantrolene sodium salt hemiheptahydrate', 'F-440', 'NSC-758403']", 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Multiple Sclerosis', 'efo_term': 'multiple sclerosis', 'approvedSymbol': 'RYR3', 'approvedName': 'ryanodine receptor 3'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.309 | Q34 | What are the names of the genes that are targeted by the drug Dexamethasone in the treatment of nephrotic syndrome? | In the context of nephrotic syndrome, the drug Dexamethasone targets the gene nuclear receptor subfamily 3 group C member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%nephrotic syndrome%" OR LOWER(efo_term) LIKE "%nephrotic syndrome%") AND (LOWER(drugName) LIKE "%dexamethasone%" OR LOWER(tradeNames_list) LIKE "%dexamethasone%" OR LOWER(syns_list) LIKE "%dexamethasone%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_227764', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228619', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228904', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229189', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229759', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230044', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230329', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230899', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231184', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231469', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_231754', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232324', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_230614', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228334', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227194', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226624', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226339', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_232039', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_229474', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_228049', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_227479', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}, {'UUID': 'DrugTargetsIndication121923_text_226909', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'syns_list': "['Decadron-LA', 'Dexacen-4', 'Dexacort', 'Dexair', 'DexamethasoneDexamethasone metasulfobenzoate sodium', 'Dexamethasone palmitateDexamethasone valerate', 'Dexycu', 'Fluormethylprednisolone', 'ISV-305Mymethasone', 'NSC-34521', 'Neodecadron', 'OTO-104']", 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Nephrotic Syndrome', 'efo_term': 'nephrotic syndrome', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1746 | Q34 | What are the names of the genes that are targeted by the drug Esomeprazole Magnesium in the treatment of gastroesophageal reflux disease? | In the context of gastroesophageal reflux disease, the drug Esomeprazole Magnesium targets the gene ATPase H+/K+ transporting subunit alpha and ATPase H+/K+ transporting subunit beta. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%gastroesophageal reflux disease%" OR LOWER(efo_term) LIKE "%gastroesophageal reflux disease%") AND (LOWER(drugName) LIKE "%esomeprazole magnesium%" OR LOWER(tradeNames_list) LIKE "%esomeprazole magnesium%" OR LOWER(syns_list) LIKE "%esomeprazole magnesium%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1097873', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097861', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha'}, {'UUID': 'DrugTargetsIndication121923_text_1097897', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}, {'UUID': 'DrugTargetsIndication121923_text_1097885', 'drugName': 'Esomeprazole Magnesium', 'tradeNames_list': "['Esomeprazole magnesium', 'Nexium', 'Nexium 24hr']", 'syns_list': "['Esomeprazole (as magnesium)', 'Esomeprazole magnesiumEsomeprazole magnesium hydrate', 'Esomeprazole magnesium trihydrateH199/18 MAGNESIUM TRIHYDRATE']", 'yearOfFirstApproval': 2001, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Gastroesophageal Reflux', 'efo_term': 'gastroesophageal reflux disease', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1315 | Q34 | What are the names of the genes that are targeted by the drug Riociguat in the treatment of pulmonary arterial hypertension? | In the context of pulmonary arterial hypertension, the drug Riociguat targets the gene guanylate cyclase 1 soluble subunit beta 1, guanylate cyclase 1 soluble subunit beta 2 (pseudogene), guanylate cyclase 1 soluble subunit alpha 2 and guanylate cyclase 1 soluble subunit alpha 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%pulmonary arterial hypertension%" OR LOWER(efo_term) LIKE "%pulmonary arterial hypertension%") AND (LOWER(drugName) LIKE "%riociguat%" OR LOWER(tradeNames_list) LIKE "%riociguat%" OR LOWER(syns_list) LIKE "%riociguat%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_972939', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972961', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972963', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972973', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972985', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972987', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972997', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973009', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973011', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973021', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973023', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973035', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973045', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973047', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973057', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973059', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973069', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973071', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973081', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973083', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973093', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973105', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973107', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973117', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973119', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973129', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973141', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973143', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973153', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973155', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973165', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973167', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973177', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973179', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973189', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973191', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973201', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973203', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973213', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973215', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973225', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973227', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973237', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973239', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973249', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973251', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973261', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973263', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973273', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973275', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973285', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973297', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973299', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973309', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973311', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973321', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973323', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973335', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973345', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973347', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973357', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973359', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973369', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973371', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973381', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973383', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973393', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973395', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973405', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973407', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973417', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973419', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973429', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973431', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973441', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973443', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973453', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973455', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973465', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973467', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973477', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973479', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973489', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973491', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973501', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973503', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973287', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973095', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972999', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972951', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972927', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972915', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972913', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973333', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)'}, {'UUID': 'DrugTargetsIndication121923_text_973131', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_973033', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972975', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972949', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972937', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}, {'UUID': 'DrugTargetsIndication121923_text_972925', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'syns_list': "['BAY 63-2521', 'BAY-63-2521', 'Riociguat']", 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension, Pulmonary', 'efo_term': 'pulmonary arterial hypertension', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1276 | Q34 | What are the names of the genes that are targeted by the drug Larotrectinib Sulfate in the treatment of neoplasm? | In the context of neoplasm, the drug Larotrectinib Sulfate targets the gene neurotrophic receptor tyrosine kinase 1, neurotrophic receptor tyrosine kinase 2 and neurotrophic receptor tyrosine kinase 3. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%neoplasm%" OR LOWER(efo_term) LIKE "%neoplasm%") AND (LOWER(drugName) LIKE "%larotrectinib sulfate%" OR LOWER(tradeNames_list) LIKE "%larotrectinib sulfate%" OR LOWER(syns_list) LIKE "%larotrectinib sulfate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_942606', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942609', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942610', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942611', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942613', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942614', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942615', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942617', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942618', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942619', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942620', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942622', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942623', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942624', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942625', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942626', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942627', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942628', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942629', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942630', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942631', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942633', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942634', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942635', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942636', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942637', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942639', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942640', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942641', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942642', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942643', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942644', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942645', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942646', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942647', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942648', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942649', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942650', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942651', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942652', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942653', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942654', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942655', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942656', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942657', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942658', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942659', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942660', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942661', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942662', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942663', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942665', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942666', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942667', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942668', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942669', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942670', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942672', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942673', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942674', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942675', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942676', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942677', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942678', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942679', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942680', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942681', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942682', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942683', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942684', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942685', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942686', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942687', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942688', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942689', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942690', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942691', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942692', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942693', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942694', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942695', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942696', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942697', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942698', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942699', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942700', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942664', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942632', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942616', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942608', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942604', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942602', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942601', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942671', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942638', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942621', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942612', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942607', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942605', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'neoplasm', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}, {'UUID': 'DrugTargetsIndication121923_text_942603', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_list': "['Vitrakvi']", 'syns_list': "['ARRY-470 SULFATE', 'LOXO-101 sulfate', 'Larotrectinib sulfate']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasm Metastasis', 'efo_term': 'metastasis', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1087 | Q34 | What are the names of the genes that are targeted by the drug Apalutamide in the treatment of cancer? | In the context of cancer, the drug Apalutamide targets the gene androgen receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cancer%" OR LOWER(efo_term) LIKE "%cancer%") AND (LOWER(drugName) LIKE "%apalutamide%" OR LOWER(tradeNames_list) LIKE "%apalutamide%" OR LOWER(syns_list) LIKE "%apalutamide%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_921857', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921866', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921867', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921872', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921876', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921877', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921882', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921886', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921887', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921892', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921893', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921897', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921902', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921903', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921906', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921907', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921912', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921913', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921916', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921917', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921922', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921926', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921927', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921932', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921933', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921936', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921942', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921943', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921946', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921947', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921952', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921953', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921956', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921957', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921962', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921963', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921923', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921883', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921863', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921853', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921847', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921846', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921937', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neoplasms', 'efo_term': 'cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921896', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921873', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921862', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921856', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}, {'UUID': 'DrugTargetsIndication121923_text_921852', 'drugName': 'Apalutamide', 'tradeNames_list': "['Erleada']", 'syns_list': "['ARN-509', 'Apalutamide', 'Arn-509', 'JNJ-56021927']", 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms, Castration-Resistant', 'efo_term': 'prostate cancer', 'approvedSymbol': 'AR', 'approvedName': 'androgen receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.655 | Q34 | What are the names of the genes that are targeted by the drug Desmopressin Acetate in the treatment of diabetes insipidus? | In the context of diabetes insipidus, the drug Desmopressin Acetate targets the gene arginine vasopressin receptor 2, arginine vasopressin receptor 1A and arginine vasopressin receptor 1B. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%diabetes insipidus%" OR LOWER(efo_term) LIKE "%diabetes insipidus%") AND (LOWER(drugName) LIKE "%desmopressin acetate%" OR LOWER(tradeNames_list) LIKE "%desmopressin acetate%" OR LOWER(syns_list) LIKE "%desmopressin acetate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_694421', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694439', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694443', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694450', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694461', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694465', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694472', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694483', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694487', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694494', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694498', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694509', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694516', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694520', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694527', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694531', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694538', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694542', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694549', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694553', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694560', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694571', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694575', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694582', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694586', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694593', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694604', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694608', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694615', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694619', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694626', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694630', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694637', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694641', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694648', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694652', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694659', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694663', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694670', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694674', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694681', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694685', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694692', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694696', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694703', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694707', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694714', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694718', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694725', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694729', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694736', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694747', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694751', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694758', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694762', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694769', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694773', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694784', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694791', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694795', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694802', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694806', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694813', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694817', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694824', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694828', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694835', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694839', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694846', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694850', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694857', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694861', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694868', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694872', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694879', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694883', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694890', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694894', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694901', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694905', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694912', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694916', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694923', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694927', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694934', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694938', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR1B', 'approvedName': 'arginine vasopressin receptor 1B'}, {'UUID': 'DrugTargetsIndication121923_text_694740', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694564', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694476', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694432', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694410', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694399', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694395', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694780', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR1A', 'approvedName': 'arginine vasopressin receptor 1A'}, {'UUID': 'DrugTargetsIndication121923_text_694597', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694505', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694454', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus', 'efo_term': 'diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694428', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694417', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_694406', 'drugName': 'Desmopressin Acetate', 'tradeNames_list': "['Concentraid', 'Ddavp', 'Ddavp (needs no refrigeration)', 'DesmomeltDesmopressin acetate', 'Desmopressin acetate (needs no refrigeration)Desmopressin acetate preservative free', 'Desmospray', 'DesmotabsMinirin', 'Nocdurna', 'Noctiva', 'Nocutil', 'Noqdirna', 'Octim', 'OctostimPresinex', 'Stimate', 'Stimate (needs no refrigeration)']", 'syns_list': "['Anhydrous desmopressin acetate', 'Desmopressin acetateDesmopressin acetate anhydrous', 'Desmopressin acetate hydrateDesmopressin acetate trihydrate']", 'yearOfFirstApproval': 1978, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Insipidus, Neurogenic', 'efo_term': 'Central diabetes insipidus', 'approvedSymbol': 'AVPR2', 'approvedName': 'arginine vasopressin receptor 2'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1834 | Q34 | What are the names of the genes that are targeted by the drug Plerixafor in the treatment of acute lymphoblastic leukemia? | In the context of acute lymphoblastic leukemia, the drug Plerixafor targets the gene C-X-C motif chemokine receptor 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%acute lymphoblastic leukemia%" OR LOWER(efo_term) LIKE "%acute lymphoblastic leukemia%") AND (LOWER(drugName) LIKE "%plerixafor%" OR LOWER(tradeNames_list) LIKE "%plerixafor%" OR LOWER(syns_list) LIKE "%plerixafor%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1103209', 'drugName': 'Plerixafor', 'tradeNames_list': "['Mozobil']", 'syns_list': "['AMD 3100', 'AMD3100', 'JM 3100', 'Plerixafor', 'Plerixafor hydrochloridePlerixafor octahydrochloride', 'SID 791']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'CXCR4', 'approvedName': 'C-X-C motif chemokine receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_1103246', 'drugName': 'Plerixafor', 'tradeNames_list': "['Mozobil']", 'syns_list': "['AMD 3100', 'AMD3100', 'JM 3100', 'Plerixafor', 'Plerixafor hydrochloridePlerixafor octahydrochloride', 'SID 791']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Lymphoma, Non-Hodgkin', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'CXCR4', 'approvedName': 'C-X-C motif chemokine receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_1103180', 'drugName': 'Plerixafor', 'tradeNames_list': "['Mozobil']", 'syns_list': "['AMD 3100', 'AMD3100', 'JM 3100', 'Plerixafor', 'Plerixafor hydrochloridePlerixafor octahydrochloride', 'SID 791']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'CXCR4', 'approvedName': 'C-X-C motif chemokine receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_1103191', 'drugName': 'Plerixafor', 'tradeNames_list': "['Mozobil']", 'syns_list': "['AMD 3100', 'AMD3100', 'JM 3100', 'Plerixafor', 'Plerixafor hydrochloridePlerixafor octahydrochloride', 'SID 791']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'CXCR4', 'approvedName': 'C-X-C motif chemokine receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_1103217', 'drugName': 'Plerixafor', 'tradeNames_list': "['Mozobil']", 'syns_list': "['AMD 3100', 'AMD3100', 'JM 3100', 'Plerixafor', 'Plerixafor hydrochloridePlerixafor octahydrochloride', 'SID 791']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'acute lymphoblastic leukemia', 'approvedSymbol': 'CXCR4', 'approvedName': 'C-X-C motif chemokine receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_1103228', 'drugName': 'Plerixafor', 'tradeNames_list': "['Mozobil']", 'syns_list': "['AMD 3100', 'AMD3100', 'JM 3100', 'Plerixafor', 'Plerixafor hydrochloridePlerixafor octahydrochloride', 'SID 791']", 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 1.0, 'mesh_heading': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma', 'efo_term': 'childhood acute lymphoblastic leukemia', 'approvedSymbol': 'CXCR4', 'approvedName': 'C-X-C motif chemokine receptor 4'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1339 | Q34 | What are the names of the genes that are targeted by the drug Capsaicin in the treatment of Muscle spasm? | In the context of Muscle spasm, the drug Capsaicin targets the gene transient receptor potential cation channel subfamily V member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%muscle spasm%" OR LOWER(efo_term) LIKE "%muscle spasm%") AND (LOWER(drugName) LIKE "%capsaicin%" OR LOWER(tradeNames_list) LIKE "%capsaicin%" OR LOWER(syns_list) LIKE "%capsaicin%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_993223', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993149', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993075', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993038', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993260', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993186', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}, {'UUID': 'DrugTargetsIndication121923_text_993112', 'drugName': 'Capsaicin', 'tradeNames_list': "['Qutenza', 'Zacin', 'Zostrix', 'Zostrix hp']", 'syns_list': "['ALGRX 4975', 'ALGRX-4975', 'Ausanil', 'Axsain', 'Capsaicin', 'Capzasin-hpCntx-4975', 'Dolenon', 'FEMA NO. 3404', 'Mioton', 'NGX-1998', 'NGX-4010NSC-56353', 'Ngx-1998', 'Ovocap', 'Ratden pe 40', 'Togarashi orenjiTrans-capsaicin']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Muscle Cramp', 'efo_term': 'Muscle spasm', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.683 | Q34 | What are the names of the genes that are targeted by the drug Infigratinib Phosphate in the treatment of cholangiocarcinoma? | In the context of cholangiocarcinoma, the drug Infigratinib Phosphate targets the gene fibroblast growth factor receptor 1, fibroblast growth factor receptor 3, fibroblast growth factor receptor 2 and fibroblast growth factor receptor 4. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%cholangiocarcinoma%" OR LOWER(efo_term) LIKE "%cholangiocarcinoma%") AND (LOWER(drugName) LIKE "%infigratinib phosphate%" OR LOWER(tradeNames_list) LIKE "%infigratinib phosphate%" OR LOWER(syns_list) LIKE "%infigratinib phosphate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_708623', 'drugName': 'Infigratinib Phosphate', 'tradeNames_list': "['Truseltiq']", 'syns_list': "['BGJ-398 phosphate', 'Infigratinib monophosphate', 'Infigratinib phosphate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_708626', 'drugName': 'Infigratinib Phosphate', 'tradeNames_list': "['Truseltiq']", 'syns_list': "['BGJ-398 phosphate', 'Infigratinib monophosphate', 'Infigratinib phosphate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_708627', 'drugName': 'Infigratinib Phosphate', 'tradeNames_list': "['Truseltiq']", 'syns_list': "['BGJ-398 phosphate', 'Infigratinib monophosphate', 'Infigratinib phosphate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_708628', 'drugName': 'Infigratinib Phosphate', 'tradeNames_list': "['Truseltiq']", 'syns_list': "['BGJ-398 phosphate', 'Infigratinib monophosphate', 'Infigratinib phosphate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_708630', 'drugName': 'Infigratinib Phosphate', 'tradeNames_list': "['Truseltiq']", 'syns_list': "['BGJ-398 phosphate', 'Infigratinib monophosphate', 'Infigratinib phosphate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_708631', 'drugName': 'Infigratinib Phosphate', 'tradeNames_list': "['Truseltiq']", 'syns_list': "['BGJ-398 phosphate', 'Infigratinib monophosphate', 'Infigratinib phosphate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_708632', 'drugName': 'Infigratinib Phosphate', 'tradeNames_list': "['Truseltiq']", 'syns_list': "['BGJ-398 phosphate', 'Infigratinib monophosphate', 'Infigratinib phosphate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_708634', 'drugName': 'Infigratinib Phosphate', 'tradeNames_list': "['Truseltiq']", 'syns_list': "['BGJ-398 phosphate', 'Infigratinib monophosphate', 'Infigratinib phosphate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_708635', 'drugName': 'Infigratinib Phosphate', 'tradeNames_list': "['Truseltiq']", 'syns_list': "['BGJ-398 phosphate', 'Infigratinib monophosphate', 'Infigratinib phosphate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_708636', 'drugName': 'Infigratinib Phosphate', 'tradeNames_list': "['Truseltiq']", 'syns_list': "['BGJ-398 phosphate', 'Infigratinib monophosphate', 'Infigratinib phosphate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_708637', 'drugName': 'Infigratinib Phosphate', 'tradeNames_list': "['Truseltiq']", 'syns_list': "['BGJ-398 phosphate', 'Infigratinib monophosphate', 'Infigratinib phosphate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_708639', 'drugName': 'Infigratinib Phosphate', 'tradeNames_list': "['Truseltiq']", 'syns_list': "['BGJ-398 phosphate', 'Infigratinib monophosphate', 'Infigratinib phosphate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_708640', 'drugName': 'Infigratinib Phosphate', 'tradeNames_list': "['Truseltiq']", 'syns_list': "['BGJ-398 phosphate', 'Infigratinib monophosphate', 'Infigratinib phosphate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_708641', 'drugName': 'Infigratinib Phosphate', 'tradeNames_list': "['Truseltiq']", 'syns_list': "['BGJ-398 phosphate', 'Infigratinib monophosphate', 'Infigratinib phosphate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_708642', 'drugName': 'Infigratinib Phosphate', 'tradeNames_list': "['Truseltiq']", 'syns_list': "['BGJ-398 phosphate', 'Infigratinib monophosphate', 'Infigratinib phosphate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708643', 'drugName': 'Infigratinib Phosphate', 'tradeNames_list': "['Truseltiq']", 'syns_list': "['BGJ-398 phosphate', 'Infigratinib monophosphate', 'Infigratinib phosphate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708644', 'drugName': 'Infigratinib Phosphate', 'tradeNames_list': "['Truseltiq']", 'syns_list': "['BGJ-398 phosphate', 'Infigratinib monophosphate', 'Infigratinib phosphate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708645', 'drugName': 'Infigratinib Phosphate', 'tradeNames_list': "['Truseltiq']", 'syns_list': "['BGJ-398 phosphate', 'Infigratinib monophosphate', 'Infigratinib phosphate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708646', 'drugName': 'Infigratinib Phosphate', 'tradeNames_list': "['Truseltiq']", 'syns_list': "['BGJ-398 phosphate', 'Infigratinib monophosphate', 'Infigratinib phosphate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708647', 'drugName': 'Infigratinib Phosphate', 'tradeNames_list': "['Truseltiq']", 'syns_list': "['BGJ-398 phosphate', 'Infigratinib monophosphate', 'Infigratinib phosphate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708648', 'drugName': 'Infigratinib Phosphate', 'tradeNames_list': "['Truseltiq']", 'syns_list': "['BGJ-398 phosphate', 'Infigratinib monophosphate', 'Infigratinib phosphate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708649', 'drugName': 'Infigratinib Phosphate', 'tradeNames_list': "['Truseltiq']", 'syns_list': "['BGJ-398 phosphate', 'Infigratinib monophosphate', 'Infigratinib phosphate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4'}, {'UUID': 'DrugTargetsIndication121923_text_708633', 'drugName': 'Infigratinib Phosphate', 'tradeNames_list': "['Truseltiq']", 'syns_list': "['BGJ-398 phosphate', 'Infigratinib monophosphate', 'Infigratinib phosphate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_708625', 'drugName': 'Infigratinib Phosphate', 'tradeNames_list': "['Truseltiq']", 'syns_list': "['BGJ-398 phosphate', 'Infigratinib monophosphate', 'Infigratinib phosphate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_708621', 'drugName': 'Infigratinib Phosphate', 'tradeNames_list': "['Truseltiq']", 'syns_list': "['BGJ-398 phosphate', 'Infigratinib monophosphate', 'Infigratinib phosphate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_708619', 'drugName': 'Infigratinib Phosphate', 'tradeNames_list': "['Truseltiq']", 'syns_list': "['BGJ-398 phosphate', 'Infigratinib monophosphate', 'Infigratinib phosphate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_708618', 'drugName': 'Infigratinib Phosphate', 'tradeNames_list': "['Truseltiq']", 'syns_list': "['BGJ-398 phosphate', 'Infigratinib monophosphate', 'Infigratinib phosphate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_708638', 'drugName': 'Infigratinib Phosphate', 'tradeNames_list': "['Truseltiq']", 'syns_list': "['BGJ-398 phosphate', 'Infigratinib monophosphate', 'Infigratinib phosphate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2'}, {'UUID': 'DrugTargetsIndication121923_text_708629', 'drugName': 'Infigratinib Phosphate', 'tradeNames_list': "['Truseltiq']", 'syns_list': "['BGJ-398 phosphate', 'Infigratinib monophosphate', 'Infigratinib phosphate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3'}, {'UUID': 'DrugTargetsIndication121923_text_708624', 'drugName': 'Infigratinib Phosphate', 'tradeNames_list': "['Truseltiq']", 'syns_list': "['BGJ-398 phosphate', 'Infigratinib monophosphate', 'Infigratinib phosphate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_708622', 'drugName': 'Infigratinib Phosphate', 'tradeNames_list': "['Truseltiq']", 'syns_list': "['BGJ-398 phosphate', 'Infigratinib monophosphate', 'Infigratinib phosphate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}, {'UUID': 'DrugTargetsIndication121923_text_708620', 'drugName': 'Infigratinib Phosphate', 'tradeNames_list': "['Truseltiq']", 'syns_list': "['BGJ-398 phosphate', 'Infigratinib monophosphate', 'Infigratinib phosphate']", 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cholangiocarcinoma', 'efo_term': 'cholangiocarcinoma', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1655 | Q34 | What are the names of the genes that are targeted by the drug Abiraterone Acetate in the treatment of prostate cancer? | In the context of prostate cancer, the drug Abiraterone Acetate targets the gene cytochrome P450 family 17 subfamily A member 1. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%prostate cancer%" OR LOWER(efo_term) LIKE "%prostate cancer%") AND (LOWER(drugName) LIKE "%abiraterone acetate%" OR LOWER(tradeNames_list) LIKE "%abiraterone acetate%" OR LOWER(syns_list) LIKE "%abiraterone acetate%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1094288', 'drugName': 'Abiraterone Acetate', 'tradeNames_list': "['Yonsa', 'Zytiga']", 'syns_list': "['Abiraterone acetate', 'CB-7630', 'CB7630', 'NSC-748121', 'NSC-749227']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'CYP17A1', 'approvedName': 'cytochrome P450 family 17 subfamily A member 1'}, {'UUID': 'DrugTargetsIndication121923_text_1094283', 'drugName': 'Abiraterone Acetate', 'tradeNames_list': "['Yonsa', 'Zytiga']", 'syns_list': "['Abiraterone acetate', 'CB-7630', 'CB7630', 'NSC-748121', 'NSC-749227']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'CYP17A1', 'approvedName': 'cytochrome P450 family 17 subfamily A member 1'}, {'UUID': 'DrugTargetsIndication121923_text_1094301', 'drugName': 'Abiraterone Acetate', 'tradeNames_list': "['Yonsa', 'Zytiga']", 'syns_list': "['Abiraterone acetate', 'CB-7630', 'CB7630', 'NSC-748121', 'NSC-749227']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'prostate cancer', 'approvedSymbol': 'CYP17A1', 'approvedName': 'cytochrome P450 family 17 subfamily A member 1'}, {'UUID': 'DrugTargetsIndication121923_text_1094296', 'drugName': 'Abiraterone Acetate', 'tradeNames_list': "['Yonsa', 'Zytiga']", 'syns_list': "['Abiraterone acetate', 'CB-7630', 'CB7630', 'NSC-748121', 'NSC-749227']", 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Prostatic Neoplasms', 'efo_term': 'metastatic prostate cancer', 'approvedSymbol': 'CYP17A1', 'approvedName': 'cytochrome P450 family 17 subfamily A member 1'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1578 | Q34 | What are the names of the genes that are targeted by the drug Everolimus in the treatment of breast neoplasm? | In the context of breast neoplasm, the drug Everolimus targets the gene FKBP prolyl isomerase 1A. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%breast neoplasm%" OR LOWER(efo_term) LIKE "%breast neoplasm%") AND (LOWER(drugName) LIKE "%everolimus%" OR LOWER(tradeNames_list) LIKE "%everolimus%" OR LOWER(syns_list) LIKE "%everolimus%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1088734', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085359', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088066', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086041', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085224', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089011', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086454', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085771', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087796', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085899', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088194', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087249', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085494', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088749', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084954', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088869', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086311', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089019', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085636', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089139', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085239', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085764', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086709', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084961', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087804', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085096', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085906', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088336', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085374', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087121', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086034', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088344', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1084969', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088464', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087391', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089004', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086176', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086184', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085509', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088884', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086304', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088876', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086319', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089274', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085231', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086439', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086446', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089154', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085644', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089146', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086574', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086589', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087654', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087534', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087669', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086716', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086724', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087939', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086844', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086851', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086859', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087931', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085366', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086979', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086986', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088606', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085914', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088074', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087114', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088329', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087129', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088209', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088201', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088599', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087256', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087264', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086049', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088479', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087384', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088471', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087399', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089281', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085501', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087519', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087526', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089409', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1089289', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088614', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088059', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087789', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087661', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086581', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085089', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085779', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1087924', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085104', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1088741', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast neoplasm', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1085629', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086994', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast cancer', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}, {'UUID': 'DrugTargetsIndication121923_text_1086169', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'syns_list': "['40-o-(2-hydroxyethyl)-rapamycin', 'Everolimus', 'RAD 666', 'RAD-001RAD-666', 'RAD001', 'SDZ-RAD', 'Sdz rad']", 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Breast Neoplasms', 'efo_term': 'breast carcinoma', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Q34.1900 | Q34 | What are the names of the genes that are targeted by the drug Latanoprost in the treatment of hypertension? | In the context of hypertension, the drug Latanoprost targets the gene prostaglandin F receptor. | SELECT DISTINCT UUID, drugName, tradeNames_list, syns_list, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term, approvedSymbol, approvedName
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(mesh_heading) LIKE "%hypertension%" OR LOWER(efo_term) LIKE "%hypertension%") AND (LOWER(drugName) LIKE "%latanoprost%" OR LOWER(tradeNames_list) LIKE "%latanoprost%" OR LOWER(syns_list) LIKE "%latanoprost%")
ORDER BY max_phase_for_ind DESC
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1149119', 'drugName': 'Latanoprost', 'tradeNames_list': "['Latanoprost', 'Monopost', 'Xalatan', 'Xelpros']", 'syns_list': "['Latanoprost', 'Latanoprost (isopropyl ester)', 'PHXA-41', 'PHXA41', 'T-2345T2345', 'XA-41', 'XA41']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149125', 'drugName': 'Latanoprost', 'tradeNames_list': "['Latanoprost', 'Monopost', 'Xalatan', 'Xelpros']", 'syns_list': "['Latanoprost', 'Latanoprost (isopropyl ester)', 'PHXA-41', 'PHXA41', 'T-2345T2345', 'XA-41', 'XA41']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149113', 'drugName': 'Latanoprostene Bunod', 'tradeNames_list': "['Vesneo', 'Vyzulta']", 'syns_list': "['BOL-303259-X', 'Bol-303259-x', 'Latanoprostene bunod', 'NCX 116', 'NCX-116PF-3187207']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149107', 'drugName': 'Latanoprostene Bunod', 'tradeNames_list': "['Vesneo', 'Vyzulta']", 'syns_list': "['BOL-303259-X', 'Bol-303259-x', 'Latanoprostene bunod', 'NCX 116', 'NCX-116PF-3187207']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149104', 'drugName': 'Latanoprostene Bunod', 'tradeNames_list': "['Vesneo', 'Vyzulta']", 'syns_list': "['BOL-303259-X', 'Bol-303259-x', 'Latanoprostene bunod', 'NCX 116', 'NCX-116PF-3187207']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149123', 'drugName': 'Latanoprost', 'tradeNames_list': "['Latanoprost', 'Monopost', 'Xalatan', 'Xelpros']", 'syns_list': "['Latanoprost', 'Latanoprost (isopropyl ester)', 'PHXA-41', 'PHXA41', 'T-2345T2345', 'XA-41', 'XA41']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149117', 'drugName': 'Latanoprost', 'tradeNames_list': "['Latanoprost', 'Monopost', 'Xalatan', 'Xelpros']", 'syns_list': "['Latanoprost', 'Latanoprost (isopropyl ester)', 'PHXA-41', 'PHXA41', 'T-2345T2345', 'XA-41', 'XA41']", 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Hypertension', 'efo_term': 'hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}, {'UUID': 'DrugTargetsIndication121923_text_1149110', 'drugName': 'Latanoprostene Bunod', 'tradeNames_list': "['Vesneo', 'Vyzulta']", 'syns_list': "['BOL-303259-X', 'Bol-303259-x', 'Latanoprostene bunod', 'NCX 116', 'NCX-116PF-3187207']", 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Ocular Hypertension', 'efo_term': 'ocular hypertension', 'approvedSymbol': 'PTGFR', 'approvedName': 'prostaglandin F receptor'}] | general | Distinct, Multi-Filter, Similarity Search, Order By | Metadata |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.